Minko Tamara, Paranjpe Pankaj V, Qiu Bo, Lalloo Anita, Won Roney, Stein Stanley, Sinko Patrick J
Center for Biomaterials, 610 Taylor Road, Piscataway, NJ 08854, USA.
Cancer Chemother Pharmacol. 2002 Aug;50(2):143-50. doi: 10.1007/s00280-002-0463-1. Epub 2002 Jun 11.
Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity in vivo limit its delivery to cancer cells. To increase the anticancer efficacy of CPT a special drug delivery system is needed.
To synthesize a novel camptothecin-poly(ethylene glycol) conjugate (CPT-PEG) which includes biotin as a moiety to enhance nonspecific and/or targeted uptake via the sodium-dependent multivitamin transporter (SMVT) and to evaluate its anticancer activity and apoptosis induction.
CPT-PEG and CPT-PEG-biotin conjugates were synthesized and studied in vitro in A2780 sensitive and A2780/AD multidrug-resistant human ovarian carcinoma cells. Cytotoxicity, apoptosis induction, expression of genes encoding BCL-2 and apoptotic protease-activating factor 1 (APAF-1) proteins and caspases 3 and 9 as well as caspase activity were measured.RESULTS. We found that the conjugation of CPT with a simple linear PEG polymer led to a more than 12-fold enhancement of CPT toxicity in both sensitive and multidrug-resistant cells. Biotinylation of the PEG led to a further increase in CPT toxicity (5.2 times in sensitive and 2.1 times in multidrug-resistant cells) compared to the nonbiotinylated CPT-PEG conjugate. As a result, the cytotoxicity of the CPT-PEG-biotin conjugate increased more than 60 times in sensitive and almost 30 times in resistant cells, probably by enhancing nonspecific passive and/or SMVT-mediated uptake. In contrast, the same amounts of PEG and PEG-biotin conjugates without CPT did not induce cell death in either sensitive or resistant cells. Further analysis showed that the biotinylated CPT-PEG conjugate induced apoptosis more significantly than the same equivalent concentrations of free CPT or nonbiotinylated CPT-PEG. The enhancement of proapoptotic activity was achieved by the overexpression of genes encoding the APAF-1, and caspases 3 and 9, increasing caspase activity and simultaneously downregulating the BCL-2 gene.
The results obtained demonstrate that the binding of CPT to PEG/PEG-biotin polymers increases its cytotoxicity, ability to induce apoptosis by the activation of caspase-dependent cell death signaling pathway and simultaneous suppression of antiapoptotic cellular defense. This suggests that the targeting approach utilizing transporters such as SMVT may substantially improve the delivery of CPT and its anticancer activity by enhancing cellular permeability and possibly retention of CPT.
喜树碱(CPT)是一种抗癌药物,它通过将DNA拓扑异构酶I转化为一种DNA损伤剂来杀死细胞。尽管CPT及其衍生物目前正被用于多种临床方案中治疗肿瘤,但该药物的低水溶性及其在体内独特的药效学和反应性限制了其向癌细胞的递送。为了提高CPT的抗癌疗效,需要一种特殊的药物递送系统。
合成一种新型的喜树碱-聚乙二醇缀合物(CPT-PEG),其中包含生物素作为部分,以增强通过钠依赖性多种维生素转运蛋白(SMVT)的非特异性和/或靶向摄取,并评估其抗癌活性和诱导凋亡的能力。
合成了CPT-PEG和CPT-PEG-生物素缀合物,并在体外对A2780敏感和A2780/AD多药耐药的人卵巢癌细胞进行了研究。测量了细胞毒性、凋亡诱导、编码BCL-2和凋亡蛋白酶激活因子1(APAF-1)蛋白以及半胱天冬酶3和9的基因表达以及半胱天冬酶活性。
我们发现CPT与简单的线性PEG聚合物缀合导致在敏感和多药耐药细胞中CPT毒性增强了12倍以上。与未生物素化的CPT-PEG缀合物相比,PEG的生物素化导致CPT毒性进一步增加(敏感细胞中增加5.2倍,多药耐药细胞中增加2.1倍)。结果,CPT-PEG-生物素缀合物的细胞毒性在敏感细胞中增加了60倍以上,在耐药细胞中增加了近30倍,可能是通过增强非特异性被动和/或SMVT介导的摄取。相比之下,相同量的不含CPT的PEG和PEG-生物素缀合物在敏感或耐药细胞中均未诱导细胞死亡。进一步分析表明,生物素化的CPT-PEG缀合物比相同等效浓度的游离CPT或未生物素化的CPT-PEG更显著地诱导凋亡。促凋亡活性的增强是通过编码APAF-1、半胱天冬酶3和9的基因的过表达、增加半胱天冬酶活性以及同时下调BCL-2基因来实现的。
获得的结果表明,CPT与PEG/PEG-生物素聚合物的结合增加了其细胞毒性、通过激活半胱天冬酶依赖性细胞死亡信号通路诱导凋亡的能力以及同时抑制抗凋亡细胞防御的能力。这表明利用诸如SMVT等转运蛋白的靶向方法可能通过增强细胞通透性以及可能增加CPT的滞留来显著改善CPT的递送及其抗癌活性。